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Abstract
Saponins are a broad class of functionally diverse phytochemicals that have been
shown to exhibit antihyperglycemic, antihyperlipidemic, anti-inflammatory, and anticancer effects. Through in vitro and in vivo experimentation, Astragaloside IV (AsIV) has
been shown to regulate glycogen synthesis through protein kinase B (AKT)-mediated
phosphorylation of glycogen synthase kinase 3-beta (GSK-3β). Along with control of
glucose homeostasis, AKT activation is also an important regulator of protein synthesis via
the downstream phosphorylation of mammalian target of rapamycin (mTOR) and
ribosomal protein S6 kinase beta-1 (S6K1). Because AsIV can activate this pathway to
stimulate glucose metabolism, it is possible that it can also promote protein synthesis as
well since these two regulatory processes utilize the same pathway. In order to determine
the effect of AsIV on protein synthetic pathways, C2C12 murine muscle cells were treated
with AsIV and the phosphorylation levels of key enzymes were assessed.
We found that AsIV induced phosphorylation of key protein synthetic targets in a
time-dependent manner, with the greatest increases in phosphorylation after two hours of
AsIV treatment. However, this effect was not seen when cells were serum-starved prior to
AsIV treatment. Lastly, AsIV was able to increase GSK-3β phosphorylation in cells treated
with dexamethasone first. These findings help to further understand the molecular changes
that occur in muscle cells treated with AsIV.
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Introduction
Atrophy of skeletal muscle is a serious consequence of many conditions, such as
COPD, HIV/AIDS, chronic kidney and heart diseases, cancer, and diabetes (Schiaffino
and Mammucari 2011). There is an association between Cachexia, the involuntary body
wasting caused by chronic disease states, and poorer outcomes from these chronic
diseases (Evans et al. 2008). As such, it poses a major public health issue (Farkas et al.
2013). While the specific mortality rates vary with each different disease, from 10-15%
in COPD, to 60-80% in cancer patients (Farkas et al. 2013), cachexia occurs in 30% of
patients who die from these diseases overall (von Haehling and Anker 2010). Within the
industrialized nations of North American, Europe, and Japan, the prevalence of cachexia
is estimated to be around 1% of the populations, or nine million people (von Haehling
and Anker 2010).
Maintaining healthy muscle mass is a balance between control of synthesis and
degradation. While there is currently no single, established pathway by which body
wasting occurs, the regulation of protein synthesis may play an important role. There
appears to be an “anabolic-catabolic dysbalance” seen with cachexia, as a result of
dysfunction to multiple body systems (von Haehling and Anker 2010). In patients with
cancer or COPD cachexia, a reduction in muscle protein synthesis was an important
factor (Morrison et al. 1988), while increased muscle breakdown was also present in
cardiac cachexia (von Haehling and Anker 2010).
There are currently no medical interventions to treat muscle atrophy, only
strategies to help reverse it by either blocking the activation of pathways that lead to
protein degradation and atrophy, or stimulate the pathways that lead to protein synthesis
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and muscle hypertrophy (Glass 2003). However, this is easier said than done due to the
necessity of both growth and degradation for proper muscle homeostasis. Therefore, it is
important to understand the molecular mechanisms behind these signaling pathways
(Sitnick 2006) and to identify ways to reverse muscle wasting via these pathways.
Regulation of protein synthesis via Akt
The regulation of muscle mass requires a constant equilibrium between protein
synthesis and breakdown, and studies have shown that the Akt/mammaliam target of
rapamycin (mTOR) signaling pathway is the mechanism controlling this balance (Glass
2003). The pathway is stimulated by extracellular insulin, insulin-like growth factor 1
(IGF1), or other structural analogs that are capable of binding to and activating receptors
on the cell membrane. The IGF1-Akt1 and insulin-Akt2 pathways are interconnected and
share many of the same components. In addition, IGF1 is capable of binding to the
insulin receptor and insulin is capable of binding to the IGF1 receptor (Schiaffino and
Mammucari 2011). However, different ligands can lead to slightly different downstream
effects as IGF1 is more involved with muscle growth and insulin is more active in
glucose metabolism (Schiaffino and Mammucari 2011).
IGF binding to the IGF1 receptor (IGFR) leads to downstream activation of Akt,
which leads to increased protein synthesis, decreased protein degradation, and increased
glucose metabolism and transport (Figure 1). When IGF1 binds to its receptor, it leads to
autophosphorylation of the receptor via activation of its intrinsic tyrosine kinase activity.
This creates a docking site for insulin receptor substrate (IRS), which is then
phosphorylated by the IGF1 receptor as well. Phosphorylated IRS then activates
phosphatidylinositol-3-kinase (PI3K), which converts phosphoinositide-4,5-biphosphate
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(PIP2) into phosphoinositide-3,4,5-triphosphate (PIP3). PIP3 acts a docking site for
phosphoinositide-dependant kinase 1 (PDK-1) and Akt, allowing for PDK-1 to activate
Akt by phosphorylating it at threonine 308. These actions all occur at the inner surface of
the cell membrane.

Figure 1: Overview of the IGF1/Akt pathway. This pathway controls protein synthesis, degradation and
glucose metabolism and transport via activation of downstream target proteins. Arrows designate one
protein activating another, red lines with a perpendicular red line at the end designates one protein
inhibiting another. Modified from Sartorelli V and Fulco M. Sci. STKE 244:1-7 (2004).

Akt then increases the rate of protein synthesis via two related mechanisms. First,
Akt indirectly activates mTOR signaling, which includes two complexes: mTORC1 and
mTORC2. mTORC2 is important for Akt activation via positive feedback that
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phosphorylates Akt at serine 473, which is necessary for optimal activation of Akt.
mTORC1 is bound to Raptor and phosphorylates ribosomal protein S6 kinase beta-1
(S6K1), which promotes protein translation efficiency. mTORC1 also increases protein
synthesis via phosphorylation and subsequent inhibition of eukaryotic translation
initiation factor 4E-binding proteins (4EBP1). Inactivation of these binding proteins
blocks the inhibition of translation initiation factor 4E, allowing for the assembly of the
ribosomal complex and translation initiation.
Second, Akt promotes protein synthesis via phosphorylation and inhibition of
glycogen synthase kinase 3 beta (GSK-3β). This protein inhibits another translation
factor: eukaryotic translation initiation factor 2B, which is important for the formation of
the initial tertiary complex of mRNA and the ribosomal subunits, allowing for the
binding of the tRNAiMet to the ribosome. Therefore, inhibition of GSK-3β by mTORC1
also leads to increased protein translation.
Akt also regulates protein metabolism by decreasing the rate of protein
degradation. This is achieved via phosphorylation and inhibition of the forkhead box O
(FoxO) family of transcription factors. Specifically, FoxO3 acts on both the proteasomal
and autophagic-lysosomal pathways to induce protein degradation (Schiaffino and
Mammucari 2011). First, FoxO3 regulates the transcription of ubiquitin ligases muscle
atrophy F-box (MAFbx) and muscle ring finger 1 (MuRF1), which cause ubiquitylation
of myosin and other muscle proteins, marking them for degradation by the proteasome
(Lecker et al. 2006). Second, FoxO3 also regulates the transcription of proteins needed to
activate the autophagy-lysosome pathway. Normal autophagic activity is necessary for
removing dysfunctional organelles and preserving the integrity of muscle fibers. The net
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effect of Fox03 activation is an increase in muscle atrophy, which is inhibited by IGF1mediated Akt activation (Sandri 2011).
Significance for control of muscle growth and loss
Genetic knockout studies have provided insight into the importance of the
IGF/Akt pathway on muscle metabolism. Mice lacking the IGF1 gene, igf1, had severe
growth retardation with most mice dying shortly after birth (Lui et al. 1993). In addition,
mice possessing a mutated, inactive IGF receptor controlled by a muscle-specific
promoter had delayed growth up to three weeks of age (Fernandez et al. 2002) and
impairment of muscle regeneration in adulthood (Heron-Milhavet et al. 2010). Deletion
of the akt1gene in mice led to growth retardation (Chen et al. 2001; Cho et al. 2001a),
while akt2 deletion caused deficits in glucose metabolism without affecting growth (Cho
et al. 2001b). When both genes were knocked out, there was significant growth
retardation and atrophy of skeletal muscle (Peng et al. 2003). Additionally, in vivo studies
have confirmed that this pathway is suppressed in mouse models of muscle atrophy
(Sitnick 2006; 2009)
In comparison, activation or over-expression of this pathway can lead to muscle
growth. First, Coleman et al. (1995) used the avian skeletal α-actin gene to create a
myogenic expression vector to direct the expression of IGF1 cDNA in skeletal muscle.
This resulted in localized over-expression of IGF1 in skeletal muscle and resulted in
striated muscle hypertrophy. Second, Lai et al. (2004) transfected mice embryos with an
Akt cDNA vector controlled by the human skeletal actin promoter, creating transgenic
mice with constitutively active Akt expressed in their skeletal muscle. Again, this
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transgenic model led to increased hypertrophy of muscle fibers, as well as increased
activation of the downstream protein target S6K1.
These studies highlight the importance of these proteins in maintaining muscle
mass, and provide evidence that increased activation of the IGF1/Akt pathway can
promote protein synthesis and muscle hypertrophy. Akt is not only involved in protein
synthesis, however, it is also the pathway controlling glucose metabolism and transport.
Regulation of glucose metabolism and transport via Akt
The PI3K/Akt pathway is a highly conserved cell-signaling pathway that
facilitates glucose uptake and metabolism. It is initiated primarily by insulin and is
especially important for insulin-dependent cells like muscle, but may also be activated by
other extracellular growth factors like IGF1 (Ward and Thompson 2012; Schiaffino and
Mammucari 2011). The initial steps in this pathway are similar to those that affect protein
synthesis (see Figure 1). Extracellular growth factors bind to their cell membrane
receptors and lead to activation of PI3K. This enzyme then phosphorylates
phosphatidylinositol lipids, which eventually leads to phosphorylation and activation of
Akt.
Akt increases glucose uptake by increasing the expression of glucose transporters
(GLUT) at the cell surface. Class I facilitative glucose transporters are divided into four
isoforms: GLUT1 – GLUT4. The insulin-responsive GLUT4 is the predominant type
found at the cell surface of skeletal muscle (Navale and Paranjape 2016). In nonstumulated cells, GLUT4 is found mostly on the interior of the cell within cytoplasmic
vesicles. Akt phosphorylates AS160 (Akt substrate of 160 kDa), which inhibits it and
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causes increased exocytosis and deceased endocytosis of GLUT4 (Swiderska et al. 2018).
The net effect is increased GLUT4 transporters at the cell surface.
Akt also activates enzymes necessary for glycolysis and glycogenesis. First, Akt
increases hexokinase activity by promoting its association with mitochondria (Gottlob et
al. 2001). Hexokinase catalyzes the first reaction of glycolysis, converting glucose to
glucose 6-phosphate. Second, Akt phosphorylates and inhibits GSK-3β just like it does in
the protein synthesis pathway. In the synthesis of glycogen, GSK-3β phosphorylates and
inhibits glycogen synthase (GS). GS is a key enzyme in glycogen formation; it catalyzes
the incorporation of glucose into the glycogen chain via a α(1→4) glycosidic bond.
When active, GSK-3β inhibits glycogenesis by inhibiting GS. However, Akt inhibits
GSK-3β, so the net effect of Akt activation is an overall increase in glycogen synthesis.
It is clear that both glucose metabolism and protein synthesis share the same
upstream pathway of PI3K/Akt phosphorylation. If a compound or chemical is capable of
stimulating this pathway to improve glucose metabolism and transport, it is theoretically
possible for such a compound to stimulate this pathway to improve protein synthesis. If
so, this mechanism may represent a therapeutic target for treating muscle wasting caused
by various medical conditions and aging. Therefore, it is important to identify substances
that may in this manner. A group of compounds that may potentially elicit this effect are
called saponins.
Saponins overview
Saponins are a class of naturally occurring phytochemicals that are widely
distributed among various plant species. They are glycosides containing one or more
sugar chains attached at varying locations to an aglycone backbone. They can be broadly
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classified as either triterpenoid (Figure 2A) or steroidal (Figure 2B) based on the
structure of their aglycone backbone, called a sapogenin Both backbone types are derived
from the same 30-carbon linear precursor (Moses et al. 2014), but subsequent processing
creates one of the two backbone subtypes. Steroidal sapogenins (27C) may possess as 6ring spirostane or 5-ring furostane skeletons. The triterpenoid sapogenins contain four or
five ring backbones and are more structurally diverse (Podolak et al. 2010).
Saponins can be further classified as mono, di-, or tridesmosidic based on the
number of sugar chains they possess (Güçlü-Ustündağ and Mazza 2007). The
combination of the lipid-soluble backbone and water-soluble sugar residues makes
saponins generally amphipatic with emulsifying and foaming properties (Wang et al.
2005). However, the complexity and structural diversity of these compounds leads to a
number of other biological effects that vary from one saponin to the next, some of which
are not completely understood (Moses et al. 2014).
A:

B:
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Figure 2: Structural difference between steroidal and triterpenoid saponins. Structure of the triterpene
aglycone backbone (A), containing 30 carbons, compared to the steroid aglycone (B) containing 27
carbons. In either case, the backbone is called a sapogenin. The addition of one or more sugar chains makes
the molecule a saponin. Modified from Güçlü-Ustündağ and Mazza 2007.

Several studies have attempted to correlate biological activity with the structural
variations between different saponins (Francis et al. 2002). Collectively, saponins are
commonly researched for their cytotoxic, lipid-lowering, anti-inflammatory, and immune
system effects. Most importantly for our study, however, is the effects that saponin have
been shown to exert in glucose metabolism and transport. Matsuda et al. (1999) found
various oleanolic acid oligoglycosides to have hypoglycemic effects that acted by
increasing the release of insulin. These compounds also suppressed the transport of
glucose from the stomach to the small intestine, and glucose transfer across the brush
border of the small intestine.
Other studies have helped to delineate the molecular mechanisms by which
saponins regulate glucose metabolism and transport. Bhavsar et al. (2009b) treated
diabetic and obese mice with saponins derived from the Helicteres isora plant and found
a reduction in serum glucose and cholesterol levels. They also found changes in the gene
expression of adipsin, Glut4, and PPARγ, genes regulating glucose and lipid transport
and metabolism. In addition, Bhavsar et al. (2009a) identified changes in protein
phosphorylation in C2C12 muscle cells as a result of treatment with saponins. They
found that saponins activated the PI3k/Akt pathway to inhibit GSK-3β and stimulate
glycogen synthesis.
Astragaloside IV
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Given the evidence that saponins can activate the Akt pathway to improve glucose
metabolism and transport, it strongly suggests that these glycosides can also activate this
pathway to stimulate protein synthesis. While saponins have varying effects due to their
structural variety, we will specifically be using Astragaloside IV (AsIV). AsIV is the
main active component of the Astragalus membranaceus plant. This plant has been used
in traditional Chinese medicine for many years for the treatment of cardiovascular disease
and metabolic disorders (Ren et al. 2013), though it wasn’t until recently that AsIV was
isolated from the plant in the lab and shown to be the compound providing these
beneficial effects.
Studies have shown that AsIV exerts cardioprotective effects via inhibition of
GSK-3β and activation of the Akt pathway. First, AsIV was shown to reduce cell death
after ischemia/reperfusion injury to cardiac muscle cells via GSK-3β inhibition by
preventing mitochondrial permeability transition pore opening (He et al. 2012). AsIV
also decreased infarct size, mitochondrial swelling, and GSK-3β activity in an in vivo
model of rat myocardial ischemia/reperfusion injury (He et al. 2014). Lastly, AsIV
increased angiogenesis and cell migration in human epithelial cells subjected to hypoxia
(Zheng et al. 2011). This effect was mediated by PI3K/Akt pathway activation.
AsIV also provides its effects on glucose metabolism and transport via activation
of Akt. Du et al. (2018) used high-fat diet feeding in mice to induce adipose dysfunction,
which led to increased endogenous hepatic glucose production and lipolysis. Subsequent
AsIV treatment limited hepatic lipid accumulation and excess hepatic glucose production
via Akt activation. In addition, Zhu et al. (2016) examined the effect of AsIV in a cellular
model of insulin resistance. In C2C12 cells exposed to palmitate for 16 hours, AsIV
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facilitated glucose uptake by increasing mRNA and protein levels of the GLUT4 glucose
transporter, in turn reversing the effects created by palmitate. Again, this effect was
mediated by phosphorylation and activation of the IRS/Akt pathway.
These studies consistently show that AsIV can activate Akt and inhibit GSK-3β
via phosphorylation of the Akt pathway to provide downstream cardioprotective and
glucose regulatory effects. We therefore hypothesize that AsIV activation of the IGF/Akt
pathway in C2C12 muscle cells can also lead to downstream stimulation of protein
synthesis.

Materials and Methods
Cell Culture
C2C12 cells (CRL-1772, American Type Culture Collection (ATCC), Rockville,
MD), a murine drived skeletal muscle cell line, were grown in proliferation media (PM):
Dulbecco’s Modified Eagle Medium (DMEM) (ATCC, Rockville, MD) supplemented
with 10% fetal bovine serum and 1% Penicillin-Streptomycin (P/S) (10,000 U/ml,
Thermo Fisher Scientific, Waltham, MA). As C2C12 cells exited the proliferatory phase
upon confluency, cells were passaged at 70-80% confluence in order to expand cell
populations. To perform experimental treatments, the cells were allowed to reach 100%
confluency, after which the culture media was switched from PM to differentiation
media: DMEM supplemented with 2% horse serum (Thermo Fisher Scientific, Waltham,
MA) and 1% P/S to induce differentiation into contractile myotubes (Figure 3). Cells
were then allowed to differentiate for four days prior to treatment. All cell cultures were
incubated at 37° C and 5% CO2 at all times.
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Figure 3: Representative image of cultured cells after differentiation. After reaching 100% confluence, cells
were induced to differentiate for 4 days in DMEM supplemented with horse serum. This resulted in
differentiation into contractile myotubes visible under light microscopy (see arrows).

Reagents
AsIV and Dexamethasone (Dexa) were obtained from Cayman Chemical
Company (Ann Arbor, MI) in powdered form. AsIV was dissolved in dimethyl sulfoxide
(DMSO) to create stock concentrations of 12.5 mM. Dexa was dissolved in DMSO and
maintained in stocks of 10 mM and 100 mM. Long R3 IGF-1 (IGF1) (Millipore Sigma,
St. Louis, MO) is a recombinant analog of the human IGF-1 and was diluted in H20 at 1
mg/ml. All stock chemicals were stored at 4°C.
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Antibodies
Phosphorylation of AKT was determined with rabbit polyclonal anti-AKT (BD
Biosciences, San Jose, CA) and mouse phospho-AKT (Ser473) (Cell Signaling
Technologies, Danvers, MA). Phosphorylation of GSK-3β was determined using rabbit
polyclonal anti-GSK-3β (BD Biosciences, San Jose, CA) and phospho-GSK-3β (Ser9)
antibodies (Cell Signaling Technologies, Danvers, MA). Phosphorylation of S6K1 was
determined using rabbit polyclonal anti-S6K1 (BD Biosciences, San Jose, CA) and
phospho-S6K1 (Thr389) antibodies (Cell Signaling Technologies, Danvers, MA).
IRDye® 800 CW Infrared Dye goat anti-mouse and IRDye® 680 CW Infrared Dye goat
anti-rabbit secondary antibodies (LI-COR Biosciences, Lincoln, NE) were used for
fluorescent quantification.
Cell Treatment
Time-Course
In order to determine the ideal treatment conditions, a time-course experiment
was performed. Based on previous research, each plate was exposed to a vehicular
control (DMSO) or 12.5 µM of AsIV. ). The 12.5 µM concentration of AsIV was chosen
based on previous studies that have shown AKT activation in C2C12 myotubes using
similar concentrations (Du et al. 2018; Zhu et al. 2016). Cells were treated for zero hours
(control), 1, 2, 4, and 6 hours before harvesting the cells. Each time point was run in
duplicate. The highest level of phosphorylation was found after two hours (Figure 4), so
two hours was chosen as the optimal incubation time.
Treatment
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From the result of the time course, two hours was chosen as the optimal
incubation time for all treatments in the study. For treatment groups, cells were grown to
confluency in PM and switched to DM to induce myotube formation (Day 0). At Day 4,
cells were treated with fresh DM with 0.2% DMSO (VC), 12.5 µM AsIV, 100 ng/ml
IGF1 alone or in combination with 10 µM Dexa (Dexa alone, Dexa + AsIV or Dexa +
IGF1). Groups treated with Dexa were treated 48 hours prior to harvest starting on Day 2
to adequately inhibit Akt phosphorylation and protein synthesis prior to AsIV or IGF1
treatment for two hours (Latres et al. 2005).
Exposure to DMSO was normalized at 0.2% for all treatment groups. Each series
of experiments was repeated twice using different passages of C2C12 myotubes (p6 and
p7). Groups treated with IGF1 were also incubated for 2 hours to maintain consistency
with the AsIV treatment time. The same concentration we used, 100 ng/ml, is capable of
phosphorylating and activating mTOR in less than two hours (Miyazaki et al. 2010).
Protein Isolation and Immunoblot Analysis
After two hours of treatment, cells were lysed in a modified RIPA buffer
containing 50 mM Tris-HCl, pH 7.4, 150mM NaCL, 1 mM EDTA, 25 mM NaF, 1 mM
PMSF, 5 mM NaVO4, and 0.1% SDS. Protease Inhibitor Complex, Phosphatase Inhibitor
Complex 2 and Phosphatase Inhibitor Complex 3 (Millipore/Sigma) were also added at
10 µl/ml of buffer. Cell slurries were then centrifuged for 20 minutes at 20,000 x g at 4oC
and the supernatants containing protein were removed to a fresh tube and stored at -80oC
until use. Protein concentrations were quantified using Bradford Reagent (Thermo Fisher
Scientific, Waltham, MA) according to manufacturer directions using a microplate reader
(BioTek Instruments, Winooski, VT).
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Westerns
For immunoblot analysis, 20-30 µg of protein from the soluble fraction was
denatured for ten minutes at 70° C in SDS loading buffer. The protein was then loaded
onto a 4-15% NuPAGE BIS-TRIS protein gel (Invitrogen, Carlsbad, CA) and
electrophoresed for 60 minutes at 200 V. After separation, proteins were transferred to an
Immobilion-Fl PVDF membrane in a Transblot turbo for 30 minutes at 25V and 1 mA.
Membranes were air-dried before continuing the blotting process.
Membranes were re-wet with methanol, rinsed twice in DDH2O and stained using
the ReVERT Total Protein Stain (LI-COR Biosciences, Lincoln, NE) according to
manufacture protocol. Following the staining procedure, membranes were imaged using
the 700 channel on an Odyssey CLx Infrared Imaging System (LI-COR Biosciences) and
total lane protein was quantified to use for normalization of western blots according to
manufacturer recommendations.
Following protein staining, membranes were rinsed and incubated in Odyssey
Blocking Buffer (OBB)(LI-COR), for 1 hour. Blots were then incubated at 4oC overnight
in primary antibody solution (OBB with 0.01% Tween) with primary antibody.
Following primary incubation, membranes were washed 4 x 5 minutes in 1X TBS with
0.01% tween (TBST). After washing, membranes were incubated with secondary
antibody at 1:30,000 in OBB with 0.01% tween and 0.01% SDS for 1 hour. Membranes
were washed 4 x 5 minutes in TBST, and then rinsed in 1X TBS to remove residual
tween before air-drying. All membrane incubations were performed rocking at room
temperature unless noted. Membranes were quantified on the Odyssey CLx and
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normalized to the corresponding normalization factor, represented as relative signal units
using Image Studio Software (LI-COR).
Statistical Analysis
All data are expressed as means ± SD. Statistical significance for treatment
groups was determined by using a two-way analysis of variance for multiple comparisons
followed by a Tukey’s post hoc test. A P value of <0.05 was considered significant.

Results
AsIV optimally increases phosphorylation of Akt (S473), GSK-3β, and S6K1 after two
hours of treatment
We first performed time course experiments to determine the optimal length of
AsIV treatment for activation of the protein synthetic pathway. We found that Akt, GSK3β, and S6K1 had the highest levels of phosphorylation after 2 hours of treatment (Figure
4). Compared to controls, there were 1.4, 1.6, and 4.4-fold increases in phosphorylation at
the 2-hour time point for Akt (S473), GSK-3β, S6K1, respectively. These results suggest
that two hours is the optimal length of time for AsIV treatment for the C2C12
differentiated myotubes we are working with. Therefore, 2 hours of incubation time was
used for all subsequent experiments.
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Fold from Control

A. Akt (S473)
1.6
1.4
1.2
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0.8
0.6
0.4
0.2

Fold from Control

Fold from Control

0

2
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0

DMSO
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4 hours
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B. GSK-3β

C. S6K1

6
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4
3
2
1
0

Control
(DMSO)
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Figure 4: Time course treatment of C2C12 cells with AsIV (n=2; DMSO control: n=2). All three target
proteins showed the highest levels of phosphorylation after 2 hours of treatment. A. There was a 1.4 fold
increase in Akt (S473) activation at 2 hours. B. There was a 1.6 fold increase in GSK-3β phosphorylation,
indicating inhibition of GSK-3β. C. Lastly, there was a 4.4 fold increase in phosphorylation of S6K1.
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AsIV does not affect target protein levels in serum-starved conditions
In order to further evaluate the effects of AsIV, cultures were placed in plain
DMEM, starved of horse serum for 2 hours, then treated based on the group they
belonged to as previously described (Miyazaki 2010). In theory, this should drop the
level of baseline phosphorylation and we should therefore see a more pronounced
stimulatory effect in our AsIV and IGF1 treatment groups. IGF1 showed significantly
higher activation of Akt (P<0.001), and S6K1 (P=0.010) compared to controls. There
was greater phosphorylation of GSK-3β as well, but this was not statistically significant.
Treatment with AsIV, however, resulted in a non-significant decrease in phosphorylation
of all target proteins, compared to controls (Figure 5).
Cultures were then treated with Dexa for 48 hours to induce atrophy and inhibit
the protein synthetic pathway. Cells were then incubated with either AsIV or IGF1 in an
attempt to recover phosphorylation levels. AsIV was able to very modestly increase
phosphorylation levels of both GSK-3β and S6K1, but did not increase Akt
phosphorylation, compared to Dexa only cultures. IGF, on the other hand, was able to
significantly stimulate phosphorylation of Akt (P<0.001) and S6K1 (P<0.001) even after
Dexa treatment, as well as a non-significant increase in GSK-3β. These cultures
recovered their phosphorylation levels and showed Akt pathway activation similar to the
results found in cells only treated with IGF1.
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Fold from Control

Fold from Control

Fold from Control

A. Akt (S473)
7.00
6.00
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2.00
1.00
0.00

Control
(DMSO)

AsIV

Control
(DMSO)

AsIV

IGF
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Dexa +
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Dexa +
IGF
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Dexa +
AsIV

Dexa +
IGF
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Dexa +
AsIV

Dexa +
IGF

B. GSK-3β

2.50
2.00
1.50
1.00
0.50
0.00

IGF

C. S6K1

2

1.5

1

0.5

0

Control
(DMSO)

AsIV

IGF

Figure 5: Cells treated in serum-starved conditions (n=3). There was a decrease in phosphorylation of all
target proteins when subjected to AsIV, compared to controls. In comparison, IGF was still able to induce
phosphorylation in these conditions. However, after cells were treated with Dexa, AsIV was able to
modestly increase phosphorylation levels of both GSK-3β (B) and S6K1 (C), but did not noticeably
increase Akt (A) phosphorylation. IGF was able to recover activation after Dexa treatment in all targets, to
levels similar to cells not initially treated with Dexa.
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AsIV may affect target protein phosphorylation levels after initial treatment with
dexamethasone
In light of the results we obtained with serum-starved trials, we repeated the
experiments using cultures maintained in DMEM and 2% horse serum at all times prior to
harvest (Figure 6). As a result, we found very modest increases in Akt and GSK-3β
phosphorylation compared to controls, which were not statistically significant. However,
this effect was not seen in S6K1, which had no change in phosphorylation levels when
compared to controls. IGF1 was again able to consistently increase phosphorylation,
especially in Akt (P=0.039) and S6K1 (P=0.038), with only modest increases in GSK-3β.
Cells were then incubated with Dexa for 48 hours prior to AsIV/IGF treatment.
There was no difference in Akt phosphorylation after AsIV treatment, but considerable
increases after IGF that approached significance (P=0.067). Phosphorylation of GSK-3β
was also greatly increased in the Dexa + AsIV group (P=0.021) compared to cells only
treated with Dexa. This was the only group in which AsIV was able to stimulate
phosphorylation in a target protein to levels nearly as high as IGF. Lastly, phosphorylation
of S6K1 was mildly increased in the Dexa + AsIV group, but significantly increased in the
Dexa + IGF group (P<0.001). In no AsIV treatment group was phosphorylation levels
higher than those seen with IGF.
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Figure 6. Cells treated in the presence of Horse Serum (n=3). Cells were maintained in horse serum during
the entirety of treatment. This resulted in greater increases in both Akt and GSK-3β after AsIV treatment
compared to controls. However, it appeared that S6K1 did not increase at the same rate. In addition, the
downstream targets of GSK-3β and S6K1 were able to recover phosphorylation levels after treatment with
Dexa, especially with GSK-3β.
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Discussion
Skeletal muscle atrophy can occur as a result of aging, lack of physical activity, or
as a debilitating component of many diseases. One potential strategy for combating
muscle loss is by stimulating the cellular pathways responsible for protein synthesis. It
has been shown that the Akt/mTOR signaling pathway is the mechanism controlling the
balance between protein synthesis and degradation. Therefore, it is important to find
substances with the potential to activate this signaling pathway to promote protein
synthesis. One such compound is Astragaloside IV, a saponin phytochemical commonly
found in Astragalus membranaceus, used in traditional Chinese medicine for glucose
homeostasis. Because this saponin is capable of activating the Akt pathway to stimulate
glucose metabolism and transport, our hypothesis is that it can also stimulate downstream
activation of the protein synthetic pathway as well.
In the current study, we first looked to determine what length of AsIV treatment
time would lead to the highest increases in Akt pathway phosphorylation, if any. We
found the highest levels of phosphorylation after two hours of treatment for Akt, GSK3β, and S6K1. These results suggest that two hours of treatment is optimal for Akt
pathway activation in C2C12 muscle cells, so cultures were treated with AsIV for two
hours in all subsequent experiments.
After two hours of treatment, phosphorylation generally declined in all target
proteins. It is possible that is a result of the negative feedback loop between S6K1 and
IRS. At sufficient quantities, activated S6K1 can act as an inhibitor of IRS by
phosphorylating it at S270 (Zhang et al. 2008). This impairs the ability of the IRS to
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stimulate glucose uptake and initiate protein synthesis. This could explain the decline we
saw after two hours.
We then evaluated the effect of AsIV on myotubes subjected to serum-starved
conditions two hours prior to treatment. There should theoretically be a decrease in basal
protein synthesis activity in the absence of serum, which would lower the relative levels
of Akt pathway activation. Subsequent treatment with AsIV or IGF would then provide
an even more pronounced effect. Following serum starvation, we saw an increase in
phosphorylation levels after IGF1 treatment alone and IGF1 treatment after Dexa pretreatment. However, this was not the case for AsIV. We actually found decreases in
phosphorylation along the Akt pathway compared to controls. When cells were treated
with Dexa for 48 hours prior to AsIV treatment, there was a mild increase in
phosphorylation. This effect was most pronounced with GSK-3β.
IGF was able to stimulate the Akt pathway to similar levels whether cultures were
subjected to Dexa first or not. It was interesting to see the large effect that IGF was
capable of producing in serum-starved conditions, compared to the decreases seen in
AsIV cultures. Our hypothesis is that IGF is such a potent activator of the Akt pathway
that the composition of the media does not make a considerable difference. It appears that
IGF is still capable of activation in the absence of the growth factors provided by horse
serum. Horse serum provides cells with growth factors, proteins, and trace elements for
optimal growth and differentiation into myotubes. Although the absence of serum may
drop baseline levels of Akt activation, it may also promote cell death due to the lack of
essential elements for growth (Leicht et al. 2003; Simm et al. 1997). It is possible that
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AsIV requires the presence of these growth factors and trace elements to enhance Akt
pathway activation rather than activate from baseline levels.
We then repeated our experiments with horse serum continuously present until the
cells were ready to harvest. Although we found modest increases in phosphorylation for
Akt and GSK-3β after AsIV treatment, we found no increase in S6K1. This results is
contradictory to the results seen in the time course experiments that showed over 4 times
greater phosphorylation after 2 hours of AsIV treatment (See Figure 4). The one change
in procedure between the two experiments was that the time course was performed in 100
mm culture plates, whereas the experimental groups thereafter were cultured in 60 mm
plates. However, this should not cause such a change by itself. Similar to the serumstarved cultures, GSK-3β and S6K1 phosphorylation rose with AsIV treatment after
initial incubation with Dexa for 48 hours. This effect was again most pronounced with
GSK-3β, where Dexa + AsIV phosphorylation was nearly has high as IGF + Dexa.
It was interesting to see the profound increases in GSK-3β for the Dexa + AsIV
group, the only trial that was comparable to IGF levels (See Figure 6). This may be
related to role that GSK-3β also plays in cell survival and apoptosis. Although originally
named for its role in glycogen metabolism, GSK-3β has since been shown to play roles in
protein synthesis, cell proliferation, and cell division (Frame and Cohen 2001).
Paradoxically, GSK-3β appears to play a role in cell death and cell survival. GSK-3β
inhibition via PI3K can prevent cell death (Pap and Cooper 1998) and mice with a
homozygous deletion of GSK-3β died before birth due to apoptotic liver degeneration
(Hoeflich et al. 2000).
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As discussed previously, AsIV can provide cardioprotective effects through Akt/GSK-3β
phosphorylation. Through inhibition of GSK-3β, AsIV is capable of reducing cell death
after ischemia/reperfusion injury to cardiac muscle cells in vitro (He et al. 2012) and
minimizing cell damage in vivo (He et al. 2014). It is possible that Dexa, in addition to
inhibition of protein synthesis, also led to some cell death. This may have been enough to
stimulate AsIV to exert cell survival effects in muscle cells via GSK-3β inhibition.
It is entirely possible that AsIV can activate the Akt/GSK-3β pathway without
subsequent protein synthesis activation. A recent study looked to determine if AsIV could
protect retinal ganglion cells from oxidative injury (Hao et al. 2018). They found that
AsIV reduced the level of reactive oxygen species (ROS) and mitigated ROS-induced
changes to the mitochondria. This recent evidence is important for our study because
ROS are extremely important for IGF1-induced hypertrophy in C2C12 muscle cells in
vitro (Handayaningsih et al. 2011). IGF1 induced ROS production in C2C12 myocytes,
and treatment with additional H2O2 enhanced IGF1-induced phosphorylation of the
IGFR. This increase in phosphorylation was inhibited by the addition of antioxidants.
Future studies should assess for ROS levels in AsIV-treated muscle cells, as these
antioxidant properties may be suppressing protein synthesis and growth.
Future studies should continue to determine how AsIV affects skeletal muscles
cells, especially in the context of protein synthesis. We hope to evaluate the downstream
effects of Akt activation by measuring myotubes sizes before and after treatment, as well
as using the SUnSET method to quantify the rate of protein synthesis. SUnSET (SUrface
SEnsing of Translation) utilizes puromycin-labeled peptides and anti-puromycin
antibodies to quantify the rate of protein synthesis between cell cultures via
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immunodetection (Schmidt et al., 2009). Given the role that GSK-3β plays in cell
apoptosis, it would also be interesting to track cell survival as a result of AsIV treatment.
Protein homeostasis is a constant balance between protein synthesis and
degradation. Both are present, even in the presence of muscle growth. There is increases
in both synthesis and degradation, but a comparatively greater increase in synthesis when
there is growth. Conversly, in the presence of atrophy there will be increases in both
again, but a greater rate of degradation than synthesis. In addition to markers of protein
synthesis, further studies should therefore evaluate the effect of AsIV on markers of
protein degradation.
IGF-1 has been shown to be sufficiently capable of stimulating protein synthesis
on its own (DeVol et al. 1990), and the results of our study appear to confirm this.
Although there is promise for IGF-1 to treat muscle wasting itself, IGF-1 receptors are
ubiquitously expressed all over the body so any form of systemic treatment may affect
other tissues as well (Gross 2003). It would interesting to see if AsIV can augment the
effects of IGF-1, if muscle cells were treated with both concurrently.
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